Volume 12 Issue 5
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(5): 595-600
Tao Simei, Huang Jiwei, Li Haibo, et al. Establishment of a blood concentration detection system for everolimus in recipients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 595-600. doi: 10.3969/j.issn.1674-7445.2021.05.014
Citation: Tao Simei, Huang Jiwei, Li Haibo, et al. Establishment of a blood concentration detection system for everolimus in recipients after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 595-600. doi: 10.3969/j.issn.1674-7445.2021.05.014
shu

Establishment of a blood concentration detection system for everolimus in recipients after liver transplantation

doi: 10.3969/j.issn.1674-7445.2021.05.014

  • Department of Pharmacy, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Huang Jiwei, E-mail: 947543512@qq.com; Yang Yang, E-mail: yysysu@163.com
  • Received Date: 2021-08-26
    Available Online: 2021-09-15
  • Publish Date: 2021-09-15
    Abstract
  •   Objective  To establish a detection system of ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for everolimus concentration in whole blood of liver transplant recipients.  Methods  The proteins of samples were precipitated with methanol and zinc sulfate, and everolimus-D4 was used as the internal standard. Phenomenex Kinetex PFP column was used. The mobile phase A was water (containing 2 mmol/Lammonium formate and 0.1% formic acid), and the mobile phase B was methanol (containing 2 mmol/L ammonium formate and 0.1% formic acid). The gradient elution was performed with the flow rate of 1 mL/min, the column temperature of 50 ℃ and the injection volume of 1 μL. The multi-reaction monitoring mode was used to quantitatively analyze with electrospray positive ionization. The UPLC-MS/MS detection system required only 100 μL of whole blood, and could achieve a sufficient lower limit of quantification without complicated sample preparation. The total running time was within 4.5 min. Linear regression (1/x2) analysis was performed using peak area of everolimus / peak area of everolimus-D4 (y) and concentration of everolimus/concentration of everolimus-D4 (x) to calculate the calibration function and analyze its accuracy and linear relationship. UPLC-MS/MS was used to detect the trough blood concentration of everolimus in blood samples of 5 recipients after liver transplantation.  Results  The accuracy of quality control was within 15%, and the linear relationship of everolimus was good in the blood concentration range of 1-100 ng /mL(R2 > 0.990). Trough blood concentration of everolimus measured in blood samples of 5 liver transplant recipients ranged from 3.77 to 9.27 ng/mL.  Conclusions  The detection system of UPLC-MS/MS in this study is suitable for monitoring the concentration of everolimus in whole blood of liver transplant recipients because of its high accuracy, simple sample processing method and short detection time.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    KIM WR, LAKE JR, SMITH JM, et al. OPTN/SRTR 2013 annual data report: liver[J]. Am J Transplant, 2015, 15(Suppl 2): 1-28. DOI: 10.1111/ajt.13197.
    [2]
    沈中阳, 谷川, 郑虹, 等. 临床肝脏移植20年回顾[J]. 中华危重病急救医学, 2019, 31(3): 269-280. DOI: 10.3760/cma.j.issn.2095-4352.2019.03.004.

    SHEN ZY, GU C, ZHENG H, et al. A twenty-year review of clinical liver transplantation[J]. Chin Crit Care Med, 2019, 31(3): 269-280. DOI: 10.3760/cma.j.issn.2095-4352.2019.03.004.
    [3]
    赵东, 夏强. 肝移植相关领域的研究进展[J]. 国际消化病杂志, 2020, 40(2): 71-74. DOI: 10.3969/j.issn.1673-534X.2020.02.001.

    ZHAO D, XAI Q. Research progress in related fields of liver transplantation[J]. Int J Dig Dis, 2020, 40(2): 71-74. DOI: 10.3969/j.issn.1673-534X.2020.02.001.
    [4]
    LEMAITRE F, VETHE NT, D'AVOLIO A, et al. Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel[J]. Ther Drug Monit, 2020, 42(5): 665-670. DOI: 10.1097/FTD.0000000000000780.
    [5]
    HOŠKOVÁ L, MÁLEK I, KOPKAN L, et al. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension[J]. Physiol Res, 2017, 66(2): 167-180. DOI: 10.33549/physiolres.933332.
    [6]
    FAROUK SS, REIN JL. The many faces of calcineurin inhibitor toxicity-what the FK?[J]. Adv Chronic Kidney Dis, 2020, 27(1): 56-66. DOI: 10.1053/j.ackd.2019.08.006.
    [7]
    中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
    [8]
    HASSKARL J. Everolimus[J]. Recent Results Cancer Res, 2018, 211: 101-123. DOI: 10.1007/978-3-319-91442-8_8.
    [9]
    ZOU Y, LI W, ZHOU J, et al. ERK inhibitor enhances everolimus efficacy through the attenuation of dNTP pools in renal cell carcinoma[J]. Mol Ther Nucleic Acids, 2019, 14: 550-561. DOI: 10.1016/j.omtn.2019.01.001.
    [10]
    CUCCHIARI D, RÍOS J, MOLINA-ANDUJAR A, et al. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice[J]. J Nephrol, 2020, 33(3): 601-610. DOI: 10.1007/s40620-019-00675-2.
    [11]
    GEDALY R, DE STEFANO F, TURCIOS L, et al. mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation[J]. Transplantation, 2019, 103(4): 705-715. DOI: 10.1097/TP.0000000000002495.
    [12]
    BENDTSEN MAF, GRIMM D, BAUER J, et al. Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma[J]. Int J Mol Sci, 2017, 18(8): 1736. DOI: 10.3390/ijms18081736.
    [13]
    TAN PS, MUTHIAH MD, KOH T, et al. Asian Liver Transplant Network clinical guidelines on immunosuppressionin liver transplantation[J]. Transplantation, 2019, 103(3): 470-480. DOI: 10.1097/TP.0000000000002532.
    [14]
    CILLO U, DE CARLIS L, DEL GAUDIO M, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group[J]. Hepatol Int, 2020, 14(6): 930-943. DOI: 10.1007/s12072-020-10091-5.
    [15]
    RUBÍN SUÁREZ A, BILBAO AGUIRRE I, FERNÁNDEZ-CASTROAGUDIN J, et al. Recommendations of everolimususe in liver transplant[J]. Gastroenterol Hepatol, 2017, 40(9): 629-640. DOI: 10.1016/j.gastrohep.2017.05.008.
    [16]
    LIN M, MITTAL S, SAHEBJAM F, et al. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: a systematic review and Meta-analysis[J]. Clin Transplant, 2017, 31(2): e12872. DOI: 10.1111/ctr.12872.
    [17]
    YU L, CHEN X, WANG L, et al. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy[J]. Oncotarget, 2016, 7(25): 38908-38926. DOI: 10.18632/oncotarget.7676.
    [18]
    FERRÍN G, GUERRERO M, AMADO V, et al. Activation of mTOR signaling pathway in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(4): 1266. DOI: 10.3390/ijms21041266.
    [19]
    VAN GELDER T, FISCHER L, SHIHAB F, et al. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation[J]. Transplant Rev (Orlando), 2017, 31(3): 151-157. DOI: 10.1016/j.trre.2017.02.007.
    [20]
    MABASA VH, ENSOM MH. The role of therapeutic monitoring of everolimus in solid organ transplantation[J]. Ther Drug Monit, 2005, 27(5): 666-676. DOI: 10.1097/01.ftd.0000175911.70172.2e.
    [21]
    FALKOWSKI S, WOILLARD JB. Therapeutic drug monitoring of everolimus in oncology: evidences and perspectives[J]. Ther Drug Monit, 2019, 41(5): 568-574. DOI: 10.1097/FTD.0000000000000628.
    [22]
    STROBBE G, PANNIER D, SAKJI I, et al. Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: a case report[J]. J Oncol Pharm Pract, 2020, 26(7): 1743-1749. DOI: 10.1177/1078155220904761.
    [23]
    GOIRAND F, ROYER B, HULIN A, et al. Level of evidence for therapeutic drug monitoring of everolimus[J]. Therapie, 2011, 66(1): 57-61. DOI: 10.2515/therapie/2010025.
    [24]
    VENTURA-AGUIAR P, CAMPISTOL JM, DIEKMANN F. Safety of mTOR inhibitors in adult solid organ transplantation[J]. Expert Opin Drug Saf, 2016, 15(3): 303-319. DOI: 10.1517/14740338.2016.1132698.
    [25]
    ARENA C, BIZZOCA ME, CAPONIO VCA, et al. Everolimus therapy and side-effects: a systematic review and Meta-analysis[J]. Int J Oncol, 2021, 59(1): 54. DOI: 10.3892/ijo.2021.5234.
    [26]
    YEE ML, TAN HH. Use of everolimus in liver transplantation[J]. World J Hepatol, 2017, 9(23): 990-1000. DOI: 10.4254/wjh.v9.i23.990.
    [27]
    NOGUERAS LÓPEZ F, ABELLAN ALFOCEA P, ORTEGA SUAZO EJ, et al. Impact of everolimus-based immunosuppression on renal function in liver transplant recipients[J]. Transplant Proc, 2020, 52(2): 556-558. DOI: 10.1016/j.transproceed.2019.12.012.
    [28]
    KOVARIK JM, TEDESCO H, PASCUAL J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation[J]. Ther Drug Monit, 2004, 26(5): 499-505. DOI: 10.1097/00007691-200410000-00007.
    [29]
    SHIPKOVA M, HESSELINK DA, HOLT DW, et al. Therapeutic drug monitoring of everolimus: a consensus report[J]. Ther Drug Monit, 2016, 38(2): 143-169. DOI: 10.1097/FTD.0000000000000260.
    [30]
    KLAWITTER J, NASHAN B, CHRISTIANS U. Everolimus and sirolimus in transplantation-related but different[J]. Expert Opin Drug Saf, 2015, 14(7): 1055-1070. DOI: 10.1517/14740338.2015.1040388.
    [31]
    JASIAK NM, PARK JM. Immunosuppression in solid-organ transplantation: essentials and practical tips[J]. Crit Care Nurs Q, 2016, 39(3): 227-240. DOI: 10.1097/CNQ.0000000000000117.
    [32]
    SATOH S, MIURA M. Therapeutic drug monitoring of immunosuppressive drugs[J]. Rinsho Byori, 2016, 64(12): 1381-1389.
    [33]
    MILLÁN O, WIELAND E, MARQUET P, et al. Pharmacodynamic monitoring of mTOR inhibitors[J]. Ther Drug Monit, 2019, 41(2): 160-167. DOI: 10.1097/FTD.0000000000000616.
    [34]
    ZHANG M, TAJIMA S, SHIGEMATSU T, et al. Development and validation of an LC-MS/MS Method to simultaneously measure tacrolimus and everolimus concentrations in kidney allograft biopsies after kidney transplantation[J]. Ther Drug Monit, 2021, DOI: 10.1097/FTD.0000000000000912[Epubaheadofprint].
    [35]
    ANTUNES NJ, KIPPER K, COUCHMAN L, et al. Simultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC-MS/MS for therapeutic drug monitoring[J]. Biomed Chromatogr, 2021, 35(6): e5071. DOI: 10.1002/bmc.5071.
    [36]
    洪顺福, 吴国兰, 郑运亮, 等. 在线固相萃取LC-MS/MS法测定健康人体全血中依维莫司浓度及在药代动力学研究中的应用[J]. 药物分析杂志, 2016, 36(10): 1778-1784. DOI: 10.16155/j.0254-1793.2016.10.11.

    HONG FS, WU GL, ZHENG YL, et al. Determination of everolimus in whole blood by online SPE LC-MS/MS system and its application in pharmacokinetic study[J]. Chin J Pharm Anal, 2016, 36(10): 1778-1784. DOI: 10.16155/j.0254-1793.2016.10.11.
    [37]
    翟晓慧, 刘晓雪, 陆佳倩, 等. LC-MS/MS法同时分析血液中几种免疫抑制剂浓度[J]. 中国医院药学杂志, 2019, 39(8): 774-780. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.08.02.

    ZHAI XH, LIU XX, LU JQ, et al. Establishment of LC-MS/MS assay for the determination of blood immunosuppressive agents level simultaneously[J]. Chin J Hosp Pharm, 2019, 39(8): 774-780. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.08.02.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (485) PDF downloads(83) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return